FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

33682311000001103: Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 04-Jan 2017. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
102527501000001113 Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
102527601000001112 Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has specific active ingredient Dapagliflozin propanediol monohydrate true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Is a Saxagliptin 5mg / Dapagliflozin 10mg tablets true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has specific active ingredient Saxagliptin hydrochloride false Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has specific active ingredient Dapagliflozin propanediol monohydrate false Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Saxagliptin true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Dapagliflozin false Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Is a Qtern true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has active ingredient Saxagliptin true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has active ingredient Dapagliflozin true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has manufactured dose form Tablet false Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has basis of strength substance Saxagliptin true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has basis of strength substance Dapagliflozin true Inferred relationship Existential restriction modifier
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Has specific active ingredient Saxagliptin hydrochloride true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) 28 tablet 2 x 14 tablets Has AMP True Qtern 5mg/10mg tablets (AstraZeneca UK Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start